Interaction between a MAPT variant causing frontotemporal dementia and mutant APP affects axonal transport
Open accessThe DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Abstract
In Alzheimer's disease, many indicators point to a central role for poor axonal transport, but the potential for stimulating axonal transport to alleviate the disease remains largely untested. Previously, we reported enhanced anterograde axonal transport of mitochondria in 8- to 11-month-old MAPT P301L knockin mice, a genetic model of frontotemporal dementia with parkinsonism-17T. In this study, we further characterized the axonal transport of mitochondria in younger MAPT P301L mice crossed with the familial Alzheimer's disease model, TgCRND8, aiming to test whether boosting axonal transport in young TgCRND8 mice can alleviate axonal swelling. We successfully replicated the enhancement of anterograde axonal transport in young MAPT P301L/P301L knockin animals. Surprisingly, we found that in the presence of the amyloid precursor protein mutations, MAPT P301L/P3101L impaired anterograde axonal transport. The numbers of plaque-associated axonal swellings or amyloid plaques in TgCRND8 brains were unaltered. These findings suggest that amyloid-β promotes an action of mutant tau that impairs axonal transport. As amyloid-β levels increase with age even without amyloid precursor protein mutation, we suggest that this rise could contribute to age-related decline in frontotemporal dementia.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Karran, E., Mercken, M., & Strooper, B. D. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3505 · Cited by 2,188 · cited 1×
“Previously, it was suggested that tau may lie downstream of APP/Ab or on a necessary pathway that converges onto a common, downstream target (Karran et al., 2011; Morris et al., 2011).”
Masters, C. L., Bateman, R., Blennow, K., Rowe, C. C., Sperling, R. A., & Cummings, J. L. (2015) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2015.56 · Cited by 1,853
Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP
Lewis, J., Dickson, D. W., Lin, W.-L., Chisholm, L., Corral, A., Jones, G., Yen, S.-H., Sahara, N., Skipper, L., Yager, D., et al. (2001) · Science · doi:10.1126/science.1058189 · Cited by 1,611 · cited 1×
“It is worth noting that alternative models that overexpress both mutant APP andMAPTP301L show late development of tau tangles; a double transgenic requiring 9 months and a different 3 Tg model not showing pathology until 12 months of age (Lewis et al., 2001; Oddo et al., 2003).”
Formation of Neurofibrillary Tangles in P301L Tau Transgenic Mice Induced by Aβ42 Fibrils
Götz, J., Chen, F., van Dorpe, J., & Nitsch, R. M. (2001) · Science · doi:10.1126/science.1062097 · Cited by 1,526 · cited 1×
“Some evidence suggests that increased tau expression and/or altered tau isoform ratio aremore important for the development of neurofibrillary pathology in a mouse than is the presence of an FTDP-17T mutation (Adams et al., 2009; Gotz et al., 2001).”
Lewis, J., McGowan, E., Rockwood, J., Melrose, H., Nacharaju, P., Van Slegtenhorst, M., Gwinn-Hardy, K., Murphy, M. P., Baker, M., Yu, X., et al. (2000) · Nature Genetics · doi:10.1038/78078 · Cited by 1,371 · cited 2×
“4 Axonal swellings are a pathological feature common to human AD and to mice expressing pathogenic forms of amyloid precursor protein (APP) or tau and mice expressing ApoE4 (Lewis et al., 2000; Tesseur et al., 2000; Wirths et al., 2006).”
InfluentialChishti, M. A., Yang, D.-S., Janus, C., Phinney, A. L., Horne, P., Pearson, J., Strome, R., Zuker, N., Loukides, J., French, J., et al. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m100710200 · Cited by 955 · cited 4×
“TgCRND8 mice inherit a highly aggressive amyloidopathy caused by expression of double mutant amyloid precursor protein (APP; K670N/M671L plus V717F) (Chishti et al., 2001), leading to early dystrophic neurites and some cell death (Bellucci et al.”
InfluentialMorris, M., Maeda, S., Vossel, K., & Mucke, L. (2011) · Neuron · doi:10.1016/j.neuron.2011.04.009 · Cited by 899 · cited 1×
“Previously, it was suggested that tau may lie downstream of APP/Ab or on a necessary pathway that converges onto a common, downstream target (Karran et al., 2011; Morris et al., 2011).”
Axonal transport deficits and neurodegenerative diseases
Millecamps, S., & Julien, J.-P. (2013) · Nature Reviews Neuroscience · doi:10.1038/nrn3380 · Cited by 755 · cited 1×
“Axonal transport is impaired in several amyloid and tau mouse models, and further impairment of transport increases pathology (Adalbert and Coleman, 2013; De Vos et al., 2008; Millecamps and Julien, 2013).”
Ishihara, T., Hong, M., Zhang, B., Nakagawa, Y., Lee, M. K., Trojanowski, J. Q., & Lee, V. M.-Y. (1999) · Neuron · doi:10.1016/s0896-6273(00)81127-7 · Cited by 564 · cited 1×
“, 2007), and wild-type and frontotemporal dementia with parkinsonism (FTDP) mutant tau (Ishihara et al., 1999; Zhang et al., 2004).”
Zhang, B., Maiti, A., Shively, S., Lakhani, F., McDonald-Jones, G., Bruce, J., Lee, E. B., Xie, S. X., Joyce, S., Li, C., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0406361102 · Cited by 413 · cited 1×
“There have been encouraging results using microtubule (MT)-stabilizing agents, such as those used in the treatment of cancer, to improve axonal transport in tauopathy models (Brunden et al., 2012; Zhang et al., 2005).”
Severely dystrophic axons at amyloid plaques remain continuous and connected to viable cell bodies
Adalbert, R., Nogradi, A., Babetto, E., Janeckova, L., Walker, S. A., Kerschensteiner, M., Misgeld, T., & Coleman, M. P. (2009) · Brain · doi:10.1093/brain/awn312 · Cited by 177 · cited 5×
“, 2012) was also present in younger, 3-month-old homozygous tau knockin mice, an age when TgCRND8 shows substantial axonal swellings and an increasing plaque density (Adalbert et al., 2009).”
InfluentialTau reduction prevents Aβ-induced axonal transport deficits by blocking activation of GSK3β
Vossel, K. A., Xu, J. C., Fomenko, V., Miyamoto, T., Suberbielle, E., Knox, J. A., Ho, K., Kim, D. H., Yu, G.-Q., & Mucke, L. (2015) · Journal of Cell Biology · doi:10.1083/jcb.201407065 · Cited by 167 · cited 1×
“Recently, it was also reported that mutant tau with markedly reduced MT-binding capacity still enabled Ab-induced axonal transport deficits (Vossel et al., 2015).”
Persistent chemoneuropathy in patients receiving the plant alkaloids paclitaxel and vincristine
Boyette-Davis, J. A., Cata, J. P., Driver, L. C., Novy, D. M., Bruel, B. M., Mooring, D. L., Wendelschafer-Crabb, G., Kennedy, W. R., & Dougherty, P. M. (2013) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-012-2047-z · Cited by 148
Early axonopathy preceding neurofibrillary tangles in mutant tau transgenic mice
Leroy, K., Bretteville, A., Schindowski, K., Gilissen, E., Authelet, M., De Decker, R., Yilmaz, Z., Buée, L., & Brion, J.-P. (2007) · The American Journal of Pathology · doi:10.2353/ajpath.2007.070345 · Cited by 135
Self-citationAxonopathy in an APP/PS1 transgenic mouse model of Alzheimer’s disease
Wirths, O., Weis, J., Szczygielski, J., Multhaup, G., & Bayer, T. A. (2006) · Acta Neuropathologica · doi:10.1007/s00401-006-0041-4 · Cited by 130 · cited 2×
“4 Axonal swellings are a pathological feature common to human AD and to mice expressing pathogenic forms of amyloid precursor protein (APP) or tau and mice expressing ApoE4 (Lewis et al., 2000; Tesseur et al., 2000; Wirths et al., 2006).”
InfluentialInhibition of APP Trafficking by Tau Protein Does Not Increase the Generation of Amyloid‐β Peptides
Goldsbury, C., Mocanu, M., Thies, E., Kaether, C., Haass, C., Keller, P., Biernat, J., Mandelkow, E., & Mandelkow, E. (2006) · Traffic · doi:10.1111/j.1600-0854.2006.00434.x · Cited by 82 · cited 1×
“MAPTP301L knockin mutation does not enhance the generation of Ab1e42 in the brains of 3-month-old TgCRND8 mice (Fig 2B), consistent with previous results using overexpression of tau in FAD-APP expressing cell lines or primary neuronal cultures (Goldsbury et al., 2006).”
Cited by
Synergy between amyloid-β and tau in Alzheimer’s disease
Busche, M. A., & Hyman, B. T. (2020) · Nature Neuroscience · doi:10.1038/s41593-020-0687-6 · Cited by 1,242
Kent, S. A., Spires-Jones, T. L., & Durrant, C. S. (2020) · Acta Neuropathologica · doi:10.1007/s00401-020-02196-w · Cited by 446
Self-citationRodent models for Alzheimer disease
Götz, J., Bodea, L.-G., & Goedert, M. (2018) · Nature Reviews Neuroscience · doi:10.1038/s41583-018-0054-8 · Cited by 394
Presynaptic failure in Alzheimer's disease
Barthet, G., & Mulle, C. (2020) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2020.101801 · Cited by 74
Colon-Perez, L. M., Ibanez, K. R., Suarez, M., Torroella, K., Acuna, K., Ofori, E., Levites, Y., Vaillancourt, D. E., Golde, T. E., Chakrabarty, P., et al. (2019) · NeuroImage · doi:10.1016/j.neuroimage.2019.116138 · Cited by 41
“Reduced RD could be associated with decreased membrane permeability or atrophy-like changes in axons or dendritic processes (Adalbert et al., 2018; Zhang et al., 2017).”
Background
Metadata
- Authors
- Adalbert, R., Milde, S., Durrant, C., Ando, K., Stygelbout, V., Yilmaz, Z., Gould, S., Brion, J.-P., & Coleman, M. P.
- Venue
- Neurobiology of Aging
- Publisher
- Elsevier BV
- Published
- 2018-08
- Volume
- 68
- Pages
- 68-75
- ISSN
- 0197-4580 (ISSN-L)
- OpenAlex
- W2795693194
- Cited by
- 24
- References
- 16
- FWCI
- 2.82
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.